

To: AmeriHealth Caritas Louisiana Behavioral Health and Primary Care Providers

Date: November 1, 2024

Subject: Recommendations for Metabolic Monitoring for Children and Adolescents on Antipsychotic Medications

Summary: The American Academy of Child & Adolescent Psychiatry, the American Psychiatric Association, and the American Diabetes Association recommend regular blood glucose testing and cholesterol testing for children and adolescents who are prescribed antipsychotic medications.

Children and adolescents who take antipsychotic medication have an increased likelihood of developing obesity, hyperglycemia, dyslipidemia, and hypertension. These conditions can result in metabolic disorders and cardiovascular events in adulthood.¹ Due to the potential side effects, it is recommended to establish a baseline and monitor the child’s blood glucose and cholesterol levels at 3 and 12 months.²

This recommendation aligns with the National Committee for Quality Assurance (NCQA) HEDIS measure titled “Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E).” This measure assesses the percentage of children ages 1-17 who are prescribed antipsychotic medication AND had blood glucose and cholesterol testing. A list of antipsychotic medications that require metabolic monitoring is provided below.

Medication name (generic name):

Symbyax (fluoxetine/olanzapine)	Zyprexa (olanzapine)
Geodon (ziprasidone)	Clozaril/Versacloz (clozapine)
Seroquel (quetiapine)	Saphris (asenapine)
Compro/Compazine (prochlorperazine)	Adasuve (loxapine)
Perseris/Risperdal/Uzedy/Rykindo (risperidone)	Invega (paliperidone)
Fanapt (iloperidone)	Abilify (aripiprazole)
Aristada (aripiprazole lauroxil)	Haldol (haloperidol)
Rexulti (brexpiprazole)	Vraylar (cariprazine)
Latuda (lurasidone hydrochloride)	

Reimbursement Codes - CPT

Glucose Lab Test	80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951
HbA1c Lab Test	83036, 83037
Cholesterol Lab Test	82465, 83718, 83722, 84478
LDL-C Lab Test	80061, 83701, 83704, 83721

Please refer to the HEDIS Documentation and Coding Guidelines MY2024 on NaviNet for measure description and coding requirements. Providers should also refer to the Louisiana Medicaid fee schedule for guidance on reimbursement.

Questions:

Thank you for your continued support and commitment to the care of our members. If you have questions about this communication, please contact AmeriHealth Caritas Louisiana's Provider Services department at 1-888-922-0007 or your [Provider Network Management Account Executive](#).

References:

¹ Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents

https://www.researchgate.net/publication/374452369_Adherence_to_Recommended_Metabolic_Monitoring_of_Children_and_Adolescents_Taking_Second-Generation_Antipsychotics/link/6600ea2ef3b56b5b2d29d812/download?tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InB1YmxpY2F0aW9uIiwicGFnZSI6InB1YmxpY2F0aW9uIn19

² Practice parameters for the use of atypical antipsychotic medications in children and adolescents

https://www.aacap.org/App_Themes/AACAP/docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdf